Pfizer shares lagged behind pharma rally due to inflated expectations, one-time losses, write-offs, and the Seagen acquisition. Find out why PFE stock is a Buy.
Sanofi, Pfizer, Acelyrin and more—Chutes & Ladders fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Gilead Sciences said an independent review of interim Phase 3 data found the immunotherapy, magrolimab, led to a higher risk of death. Though Gilead is discontinuing further development of the drug in blood cancers, a review is ongoing in solid tumors.